3 Drugs Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 78 points (0.5%) at 16,438 as of Thursday, March 6, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,775 issues advancing vs. 1,148 declining with 152 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.4%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 2.3%, Mylan ( MYL), down 1.5% and Actavis ( ACT), down 1.5%. Top gainers within the industry include Teva Pharmaceutical Industries ( TEVA), up 1.6%, AbbVie ( ABBV), up 1.2%, Novartis ( NVS), up 1.2%, Merck ( MRK), up 1.0% and Amgen ( AMGN), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry lower today. As of noon trading, GlaxoSmithKline is down $0.37 (-0.7%) to $56.06 on average volume. Thus far, 1.0 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $55.96-$56.33 after having opened the day at $56.30 as compared to the previous trading day's close of $56.43.

GlaxoSmithKline plc manufactures and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $137.0 billion and is part of the health care sector. Shares are up 5.7% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst that rates GlaxoSmithKline a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full GlaxoSmithKline Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Forest Laboratories ( FRX) is down $1.14 (-1.1%) to $97.59 on light volume. Thus far, 1.0 million shares of Forest Laboratories exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $97.43-$99.00 after having opened the day at $98.75 as compared to the previous trading day's close of $98.73.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. Forest Laboratories has a market cap of $26.9 billion and is part of the health care sector. Shares are up 65.5% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Forest Laboratories a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Forest Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $0.80 (-1.0%) to $82.07 on light volume. Thus far, 2.7 million shares of Gilead exchanged hands as compared to its average daily volume of 11.6 million shares. The stock has ranged in price between $82.05-$83.42 after having opened the day at $83.22 as compared to the previous trading day's close of $82.87.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $127.6 billion and is part of the health care sector. Shares are up 10.4% year-to-date as of the close of trading on Wednesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Stocks Waver Amid a Rise in Bond Yields, Strong Earnings

Stocks Waver Amid a Rise in Bond Yields, Strong Earnings

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Video: Jim Cramer Reveals Why He's Cautious on Stocks